Generalized anxiety disorder: between now and DSM-V.
This article presents the current evidence base for pharmacotherapy of generalized anxiety disorder (GAD) and an update on the phenomenology of GAD and its association with other psychiatric and somatic conditions. It discusses nosological issues and suggests ways to improve recognition, treatment, and care for patients who have GAD.
Allgulander
Christer
C
Department of Clinical Neuroscience, Karolinska Institutet, Section of Psychiatry at Karolinska University Hospital, SE14186 Huddinge, Sweden. christer.allgulander@ki.se
D000375:Aging / Q000523:psychology; D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy*; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015897:Comorbidity; D003937:Diagnosis, Differential; D006801:Humans; D011320:Primary Health Care / Q000379:methods; D011613:Psychotherapy / Q000379:methods*
D014151:Anti-Anxiety Agents